Female libido drug nears approval with FDA panel’s backing
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.
While health insurers in states around the country have proposed large rate increases for the health plans they sell on the Obamacare exchanges, insurers in Indiana are asking for modest increases or even decreases. The bad news is that it appears the rest of the country is just catching up with Indiana’s already-high prices.
The new version of the Healthy Indiana Plan, backed by Obamacare funding, has enrolled 229,000 new participants in four months without breaking stride.
Dozens of health insurers say higher-than-expected care costs and other expenses blindsided them this year, and they're going to have to hike premiums for individual policies well-beyond 10 percent for 2016.
Wall Street analysts say a purchase of Louisville-based Humana Inc., which reportedly has put itself up for sale, would by Indianapolis-based Anthem. An Anthem-Humana marriage would be the biggest merger in the history of U.S. health insurance.
Thousands of Indiana children who raised and doted on chickens, turkeys and other poultry for 4-H projects are feeling the sting of a statewide ban on bird shows aimed at preventing the spread of a bird flu.
Central Indiana has been the birthplace of groundbreaking innovation felt nationwide–even worldwide.
It took $394,000 to rank in the top 1 percent of U.S. earners in 2013. And more than 100 of the Indiana contingent in that exclusive club were physicians employed by one of the four major hospital systems that operate in the Indianapolis area.
In the 1920s, Indianapolis was one of the most innovative cities in the nation. But after “the dark tragedy of the roaring twenties,” Indianapolis lost its edginess for decades and only recently has begun to regain it.
IBJ picked the brains of Indianapolis-area firms and organizations known for liquid thinking to discover how they open the spigot on innovation.
The drugmaker plans to sell 2.1 billion euros ($2.3 billion) of securities in three parts, according to a person familiar with the matter who asked not to be identified.
A Supreme Court ruling due in a few weeks could wipe out health insurance for millions of people covered by President Barack Obama’s health care law.
Goodwill Industries of Central Indiana Inc. is appealing a decision by the Richard L. Roudebush Veterans Affairs Medical Center that would put 63 janitors and their four managers out of work by Aug. 1.
The Indiana University Simon Cancer Center appears ill-suited for the future of cancer care and its own future is in question.
The individual hospital campuses around Indianapolis saw their collective revenue rise 8 percent and their collective operating profits rise 22 percent from from 2011 to 2013. That’s solid, just not stellar, growth.
In Indiana, Anthem has struck accountable care organization deals with 14 health care provider groups and signed up nearly 2,900 primary care providers to its medical home program. And it’s pushing for more in the future.
For employer health plans, diabetics generate $10,000 more per year in medical bills than non-diabetics. That means the rise in the prevalence of diabetes over the past 25 years is costing Hoosiers an extra $2.6 billion annually.
With a CEO hired and a soon-to-be signed lease for office space, the $360 million Indiana Biosciences Research Institute is ready to lift off.
Community Health Network said Thursday that it will spend $175 million to build a hospital on its East campus instead of renovating existing facilities. It also plans to build a $60 million cancer center on its North campus in the Castleton neighborhood.
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.